Comparing morhine and fentanyl on anti platelet effect of ticagrelor
Phase 4
Completed
- Conditions
- Health Condition 1: null- ACUTE CORONARY SYNDROMEHealth Condition 2: I21- Acute myocardial infarctionHealth Condition 3: I25- Chronic ischemic heart diseaseHealth Condition 4: I200- Unstable angina
- Registration Number
- CTRI/2018/04/013423
- Lead Sponsor
- SRI RAMACHANDRA MEDICAL COLLEGE AND RESEARCH INSTITUTIO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 136
Inclusion Criteria
Patients with acute coronary syndrome and age >18 years
Exclusion Criteria
Patients who will be in altered sensorium status due to any other pathology which prohibits them from answering questions
Patients who are already on dual anti platelet agents
Patients who have been thrombolysed or before reaching ER at SRMC
Patients who will not provide consent
Patients who would have been administered analgesics in out of hospital settings
Patients who receive Gp2b/3a inhibitors in emergency or in ambulance
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Platelet reactivity measured using light transmission aggregometry at SECOND hour between the two groupsTimepoint: SECOND HOUR
- Secondary Outcome Measures
Name Time Method 1.Comparison of pain scale amongst the groups. <br/ ><br>2.Comparison of adverse events that include nausea, vomiting, bradycardia, hypotension.Timepoint: second hour